A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs BGB 290 (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeiGene
- 12 Sep 2017 Trial design of the study, presented at the 42nd European Society for Medical Oncology Congress.
- 30 Aug 2017 According to a BeiGene media release, results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
- 09 Aug 2017 Status changed from not yet recruiting to recruiting.